RYTARY is an extended-release oral capsule formulation of carbidopa-levodopa. It is not indicated for use in patients using nonselective monoamine oxidase inhibitors (MAO) inhibitors. The drug contains immediate
The new registration trial follows positive data from the company’s completed Phase Ib/IIa VERTICAL trial as well as the ongoing long-term Extension Study. The randomized, open-label, Phase III
As part of the deal, Nuo will receive an upfront payment from Rohto in return for an exclusive license and the right to develop and commercialize Aurix in
Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE compound. It has also secured orphan designation in multiple myeloma from the European Medicines Agency (EMA).
Savaysa is an oral, once-daily selective factor Xa-inhibitor developed to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). Daiichi Sankyo
The antibiotic compound has been discovered in a screen against NovoBiotic’s extract library generated from previously uncultured microbes. NovoBiotic president Dr Dallas Hughes said: "The discovery of teixobactin
The trial, which is designed to evaluate the efficacy, safety and pharmacokinetics of mocetinostat, will enroll patients whose tumors have mutations or deletions of the CREBBP and/or EP300
Under the deal, Tetragenetics will use its ion channel production technology, SionX, to produce about five ion channel antigens for MedImmune’s antibody drug discovery programs. The company said
Targin is a fixed combination of prolonged-release oxycodone/naloxone, which is the first opioid which has been granted a licence in the EU to treat RLS. According to the
Aptiom is approved for use as adjunctive treatment of partial-onset seizures and is not approved for use as monotherapy for partial-onset seizures. The sNDA included data from two
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.